Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the cobicistat and Prezista fixed-dose combination worldwide.
Gilead is responsible to develop, manufacture and commercialize cobicistat as a stand-alone product and for use in combination with other agents.
Additionally, both the parties are also in negotiations to develop and commercialize another combined drug combining Prezista, Emtriva, GS 7340 and cobicistat.
The agreement is subject to regulatory approval.